This mechanism is particularly significant in ovarian cancer, where IgA binds to poly-IgA receptors, activates transcriptional changes within tumor cells, and inhibits the RAS pathway, thereby enhancing T cell-mediated killing and hindering tumor progression (73). Here, CD79A is linked to ovarian carcinoma.